相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities
Ruth Duncan et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors
W. T. Lim et al.
ANNALS OF ONCOLOGY (2010)
Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Laurent Ducry et al.
BIOCONJUGATE CHEMISTRY (2010)
CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes
Tatsuaki Tagami et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
Chung Hang J. Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin
Mark E. Davis
ADVANCED DRUG DELIVERY REVIEWS (2009)
ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic
David P. Nowotnik et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
siRNA Conjugate Delivery Systems
Ji Hoon Jeong et al.
BIOCONJUGATE CHEMISTRY (2009)
Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy Twenty Years of Clinical Experience
William Renwick et al.
BIODRUGS (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
Monica Mita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
L. C. Scott et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Polymeric Tubulysin-Peptide Nanoparticles with Potent Antitumor Activity
Thomas Schluep et al.
CLINICAL CANCER RESEARCH (2009)
Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models
Tontanai Numbenjapon et al.
CLINICAL CANCER RESEARCH (2009)
Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia
J. C. Panetta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Pegasparaginase: where do we stand?
Amer Zeidan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Teni Boulikas
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
Leonard W. Seymour et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production
Tatsuaki Tagami et al.
JOURNAL OF CONTROLLED RELEASE (2009)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic
Mark E. Davis
MOLECULAR PHARMACEUTICS (2009)
The Effect of Chemical Modification and Nanoparticle Formulation on Stability and Biodistribution of siRNA in Mice
Shan Gao et al.
MOLECULAR THERAPY (2009)
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Steven D. Perrault et al.
NANO LETTERS (2009)
A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma
Qinghua Zhou et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2009)
Accelerated Blood Clearance Phenomenon Upon Repeated Injection of PEG-modified PLA-nanoparticles
Tsutomu Ishihara et al.
PHARMACEUTICAL RESEARCH (2009)
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements
Thomas Schluep et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents
Rudolph L. Juliano et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2009)
Polymer-drug conjugates: Recent development in clinical oncology
Chun Li et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Nanotechnology and cancer
James R. Heath et al.
ANNUAL REVIEW OF MEDICINE (2008)
Antibody-drug conjugates for cancer therapy
Paul J. Carter et al.
CANCER JOURNAL (2008)
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11 - Refractory model
Puja Sapra et al.
CLINICAL CANCER RESEARCH (2008)
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
Erin R. Gardner et al.
CLINICAL CANCER RESEARCH (2008)
Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor - expanding uses in cancer chemotherapy
Mariko Morishita et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Pegaptanib sodium for the treatment of age-related macular degeneration
Rajendra S. Apte
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Potential of Advexin®: a p53 gene-replacement therapy in Li-Fraumeni syndrome
Jackie M. Nemunaitis et al.
FUTURE ONCOLOGY (2008)
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome
Ryo Suzuki et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives
Raghavendra C. Mundargi et al.
JOURNAL OF CONTROLLED RELEASE (2008)
Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Pharmacokinetics and biodistribution of nanoparticles
Shyh-Dar Li et al.
MOLECULAR PHARMACEUTICS (2008)
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Frank Alexis et al.
MOLECULAR PHARMACEUTICS (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
Shanta Dhar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
Keun Seok Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
D. -W. Kim et al.
ANNALS OF ONCOLOGY (2007)
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies
Jade Homsi et al.
CLINICAL CANCER RESEARCH (2007)
Renal clearance of quantum dots
Hak Soo Choi et al.
NATURE BIOTECHNOLOGY (2007)
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
Derek W. Bartlett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Impact of single-chain fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells
Yu Zhou et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Review on Medusa®:: a polymer-based sustained release technology for protein and peptide drugs
Y-P Chan et al.
EXPERT OPINION ON DRUG DELIVERY (2007)
Functionalized micellar systems for cancer targeted drug delivery
Damon Sutton et al.
PHARMACEUTICAL RESEARCH (2007)
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
Jeremy D. Heidel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases
Scott A. Shaffer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Selective tumor cell targeting using low-affinity, multivalent interactions
Coby B. Carlson et al.
ACS CHEMICAL BIOLOGY (2007)
Cardiac safety of liposomal anthracyclines
Gerald Batist
CARDIOVASCULAR TOXICOLOGY (2007)
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles
Derek W. Bartlett et al.
BIOCONJUGATE CHEMISTRY (2007)
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer
Tracy R. Daniels et al.
CLINICAL IMMUNOLOGY (2006)
The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Tracy R. Daniels et al.
CLINICAL IMMUNOLOGY (2006)
Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation and high-dose first injection
Tatsuhiro Ishida et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol)
Alisar S. Zahr et al.
LANGMUIR (2006)
A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours
S. Lowis et al.
BRITISH JOURNAL OF CANCER (2006)
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
Dmitri B. Kirpotin et al.
CANCER RESEARCH (2006)
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice
T Schluep et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes
T Ishida et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes
AA Gabizon et al.
CLINICAL CANCER RESEARCH (2006)
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models
T Schluep et al.
CLINICAL CANCER RESEARCH (2006)
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers
MR Dreher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes
A Judge et al.
MOLECULAR THERAPY (2006)
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate
Stewart D. Chipman et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2006)
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo
C Mamot et al.
CANCER RESEARCH (2005)
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
AV Boddy et al.
CLINICAL CANCER RESEARCH (2005)
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas
JA Posey et al.
CLINICAL CANCER RESEARCH (2005)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma
S Hu-Lieskovan et al.
CANCER RESEARCH (2005)
Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate
SH Kim et al.
LANGMUIR (2005)
Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids
G Gregoriadis et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2005)
Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system
MY Chen et al.
JOURNAL OF NEUROSURGERY (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability
D Venturoli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor
ES Lee et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Development and characterization of a novel liposome-based formulation of SN-38
JA Zhang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Synthesis of a macromolecular camptothecin conjugate with dual phase drug release
A. V. Yurkovetskiy et al.
MOLECULAR PHARMACEUTICS (2004)
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148):: a polymeric derivative of camptothecin (CPT)
D Bissett et al.
BRITISH JOURNAL OF CANCER (2004)
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors:: an open-label, single-dose study
K Mross et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Y Matsumura et al.
BRITISH JOURNAL OF CANCER (2004)
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
TY Kim et al.
CLINICAL CANCER RESEARCH (2004)
A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors
JM Rademaker-Lakhai et al.
CLINICAL CANCER RESEARCH (2004)
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
NE Schoemaker et al.
BRITISH JOURNAL OF CANCER (2002)
Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin
LW Seymour et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
SC Kim et al.
JOURNAL OF CONTROLLED RELEASE (2001)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
分享论文
